Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 355

The DOI matches its Crossref record.

Effects of the 5‐HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain

Open access
Costall, B., Domeney, A.M., Naylor, R.J., Tyers, M.B.·1987·British Journal of Pharmacology

Abstract

The ability of the selective 5‐HT 3 receptor antagonist GR38032F to reduce raised mesolimbic dopaminergic activity was studied in behavioural experiments in the rat and marmoset. GR38032F injected into the nucleus accumbens (0.01–1 ng) or peripherally (0.01–1 mg kg−1 i.p.) inhibited the locomotor hyperactivity caused by the acute intra‐accumbens injection of amphetamine (10 μg) in the rat. Similar treatments with sulpiride and fluphenazine also inhibited the amphetamine‐induced hyperactivity. The peripheral administration of GR38032F (0.001–0.1 mg kg−1 i.p., b.d.) during a 13 day period of dopamine infusion (25 μg 24 h−1) into the nucleus accumbens of the rat reduced the dopamine‐induced hyperactivity response to control (vehicle infused) levels. Locomotor activity remained at control levels after discontinuing the dopamine/GR38032F treatment regimen. The hyperactivity caused by the infusion of dopamine into the rat nucleus accumbens was also inhibited by fluphenazine (0.01‐0.05 mg kg−1 i.p., b.d.), but locomotor activity was suppressed to levels below control values and a rebound hyperactivity occurred after discontinuation of the dopamine/fluphenazine treatment regimen. The discontinuation of a concomitant 13 day intra‐accumbens infusion of dopamine with haloperidol, 0.01 mg kg−1 i.p. t.d.s., caused a rebound hyperactivity. This hyperactivity was suppressed by GR38032F (0.001‐0.1 mg kg−1 i.p.). The unilateral infusion of dopamine (25 μg 24 h−1, 13 days) into the left amygdala of rats having right hemispheric dominance (as measured in a turn preference test) caused locomotor hyperactivity. Intraperitoneal administration of GR38032F (0.1–100 μg kg−1) or fluphenazine (0.025‐0.1 mg kg−1), and the intra‐amygdaloid injection of GR38032F (0.1–100 ng) or fluphenazine (25–500 pg), either into the infused or non‐infused side, inhibited the dopamine‐induced locomotor hyperactivity. Marmosets receiving bilaterial infusions of dopamine (25 μg 24 h−1 for 13 days) into the nucleus accumbens also exhibited increased locomotor activity. GR38032F (0.1‐1.0 μg kg−1 t.d.s.), reduced the hyperactivity to control levels with no rebound hyperactivity following the discontinuation of the dopamine/GR38032F treatment regimen. Fluphenazine (0.01–2.5 mg kg−1 i.p., t.d.s.) also inhibited the hyperactivity, but locomotor activity was reduced to values below control levels and a rebound hyperactivity followed the discontinuation of the dopamine/fluphenazine treatment. It is concluded that the 5‐HT 3 receptor antagonist GR38032F, and the neuroleptic agents fluphenazine, sulpiride and haloperidol, can reduce raised mesolimbic dopaminergic activity in the rat and marmoset. GR38032F is distinguished from the dopamine receptor antagonists by, firstly, its ability to return the hyperactivity response to control values, without excessive suppression of locomotion even on enhanced dosage regimes and, secondly, by the lack of rebound hyperactivity following abrupt discontinuation of its treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.1987.tb11394.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 355

Metadata

Authors
Costall, B., Domeney, A. M., Naylor, R. J., & Tyers, M. B.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
1987-12
Volume
92
Issue
4
Pages
881-894
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2024562186
Cited by
355
References
0
FWCI
8.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of the 5‐HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. https://app.cochat.ai/papers/10.1111/j.1476-5381.1987.tb11394.x
The paper
Costall, B., Domeney, A. M., Naylor, R. J., & Tyers, M. B. (1987). Effects of the 5‐HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.1987.tb11394.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.